Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03955627 · ClinicalTrials.gov registry record · NA
REJOIN Trial for Older Breast Cancer Survivors
A NA study of Breast Cancer Female, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT03955627 is a NA study of Breast Cancer Female that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 12 participants, below the 692-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03955627, a NA study of Breast Cancer Female, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this pilot intervention study is to test the effectiveness of a self-management approach (combining education- and exercise-based strategies) for improving arthralgia (joint pain) associated with Aromatase Inhibitors (AI) in older breast cancer survivors. Survivors will be recruited from local cancer clinics prior to the completion of primary cancer treatment, as arthralgia can occur soon after initiating AI medication. Participants will be randomized to one of two groups: an enhanced standard care group (AI prescription plus information) or a treatment group (educational classes plus group exercise sessions). Older survivors (≥60 years) will be targeted because they are at increased risk of medication complications which may impede adherence. For the baseline assessment, a cancer-specific geriatric assessment will be conducted and a blood sample will be collected to interpret the effects of the self-management study in the context of geriatric experiences. Additionally, there will be an assessment of knowledge, PA habits, and AI-related joint pain and AI adherence. These will be measured again at 4, 6 and at follow up at 12 months.
Conditions Studied
Interventions
- BEHAVIORAL Relieving Joint Pain and Improving AI Adherence in Older Breast Cancer Survivors (REJOIN)
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-06-15 |
| Est. Completion | 2025-07-29 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03955627
The ClinicalTrials.gov registry entry for NCT03955627 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 692-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (98% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer Female appearing as the primary indexed condition, and to 1 intervention - of which Relieving Joint Pain and Improving AI Adherence in Older Breast Cancer Survivors (REJOIN) is the first listed.
NCT03955627 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT03955627 about?
NCT03955627 is a clinical study titled "REJOIN Trial for Older Breast Cancer Survivors". The purpose of this pilot intervention study is to test the effectiveness of a self-management approach (combining education- and exercise-based strategies) for improving arthralgia (joint pain) associated with Aromatase Inhibitors (AI) in older breast cancer survivors. Survivors will be recruited f...
What is the current status of trial NCT03955627?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2021-06-15. Estimated completion is 2025-07-29.
What conditions does trial NCT03955627 study?
This clinical trial studies the following conditions: Breast Cancer Female.
What interventions are being tested in trial NCT03955627?
The interventions under investigation include: Relieving Joint Pain and Improving AI Adherence in Older Breast Cancer Survivors (REJOIN) (BEHAVIORAL).
Who is sponsoring clinical trial NCT03955627?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03955627 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Female
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Breast Cancer Resiliency Through Exercise Program (B-REP)
RECRUITING · NA
-
Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women
RECRUITING · NA
-
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
RECRUITING · NA
-
Cognitive Rehabilitation Following Breast Cancer Treatment
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.